Method for extracting IgM (Immunoglobulin M) from bovine blood

Through polyethylene glycol fractionated precipitation and hydroxyapatite elution, the problem of low purity and recovery of IgM in bovine blood was solved, and high purity and high recovery of IgM preparation was achieved, which was suitable for drug development and clinical applications.

CN118909101AInactive Publication Date: 2024-11-08GUANGZHOU RUITE BIOTECH CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411324562.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

When extracting IgM from cattle blood, the prior art has low purity, low recovery rate, low activity retention rate, and low industrial economic benefits, making it difficult to meet the high-precision needs.

Method used

The combination of polyethylene glycol (PEG) fractional precipitation method and hydroxyapatite (HPA) elution method is used to remove impurity proteins in plasma through multi-step fine regulation and combination innovation, and improve the purity and recovery of IgM.

Benefits of technology

The purity of IgM is achieved by reaching more than 95%, the recovery rate is increased to 85%-90%, and the biological activity is effectively retained, the operation is simplified, the cost is reduced, and it is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909101A_ABST
    Figure CN118909101A_ABST
Patent Text Reader

Abstract

The invention relates to a method for extracting IgM (Immunoglobulin M) from cattle blood, which comprises the following steps: S10, adding an anticoagulant into fresh adult cattle blood, uniformly mixing, centrifuging, and collecting supernate to obtain a plasma solution; s20, carrying out crude extraction on the plasma solution through a 3-9% polyethylene glycol fractional precipitation method, and redissolving and precipitating with a phosphate buffer solution to obtain a crude extract; and S30, eluting the crude extract by using a hydroxyapatite column, collecting the eluent, and carrying out ultrafiltration concentration to obtain an IgM concentrated solution. Compared with the prior art, the method has the advantages that impurity proteins, such as bovine immune protein compounds, fibrin, bovine albumin and bovine IgG, in plasma are effectively removed through a method of combining fractional precipitation of polyethylene glycol (PEG) and elution of hydroxyapatite (HPA), so that the IgM with the purity of 95% or above is prepared, and in addition, the purity of the IgM is greatly improved. According to the extraction and purification process, the recovery rate of the IgM is increased to 85%-90%, efficient utilization of bovine blood resources is facilitated, and the production efficiency and economic benefits of the IgM are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of antibodies, and in particular to a method for extracting IgM from bovine blood. Background Art

[0002] my country raises nearly 200 million cattle and sheep every year. At the end of 2018, the number of cattle in my country was 105.76 million, and about 13.63 million beef cattle were slaughtered. If the total bleeding volume of cattle is calculated as 4.2% of the body weight of live cattle, the blood collection volume per cattle is 11-15 kg, and the calf is about 2.7 kg. my country can obtain 572,500 tons of cattle blood every year. However, due to the strong bloody smell of cattle blood, poor digestibility and palatability, poor color and sensory perception, and the difficulty of preserving raw blood, only a small amount of blood is processed into food, and a large amount of blood is discarded, which seriously restricts the comprehensive utilization of cattle blood resources, and direct discharge increases the environmental burden. Therefore, the comprehensive development and utilization of cattle blood resources is of great significance and will be the current and future development trend.

[0003] A large number of studies have shown that immunoglobulins can agglutinate bacteria, neutralize bacterial toxins, and can completely kill bacteria and viruses, activate complement, and enhance the body's immune function with the participation of other factors in the body. Immunoglobulins are composed of heavy chains and light chains, and according to the different chemical structures of the constant region of the heavy chain (H chain), the corresponding immunoglobulins are divided into multiple types: immunoglobulin M (IgM), immunoglobulin D (IgD), immunoglobulin A (IgA), immunoglobulin E (IgE), and immunoglobulin G (IgG). Among them, IgG has the highest content, accounting for about 75% of the total Ig in serum, and is the main antibody in humoral immunity; IgM accounts for about 10%, and is the first antibody produced by the body after being stimulated by antigens. It plays a "pioneer immunity" role and has strong cytotoxic and cell lytic activities. Its bactericidal, bacteriolytic, phagocytic and agglutinative effects are 500 to 1000 times stronger than IgG, and it is a highly effective antimicrobial antibody. IgM (immunoglobulin M) is a pentamer composed of five monomers connected by a J chain and a disulfide bond. Its molecular weight is the largest among the five types of immunoglobulins, at 970 kD, and is called macroglobulin. This structure enables immunoglobulin M to have more antigen binding valences, and it can bind to several target cells at the same time, playing the role of the main antibody in the body's anti-infection immunity. Therefore, extracting IgM from bovine blood to prepare Ig preparations rich in IgM can provide an ideal drug for preventing and treating bacterial infections, and can make more effective use of bovine blood resources.

[0004] Traditional methods for extracting immunoglobulins from blood, such as salting-out, organic solvent and ion exchange chromatography, each have their own advantages and limitations. Although the salting-out method and the organic solvent method are widely used in the initial extraction stage with low cost and simple operation as the highlights, the purity and purification efficiency of the obtained immunoglobulins are often unsatisfactory, which limits their application in high-precision demand scenarios. Although ion exchange chromatography can provide a certain degree of purification, it faces separation challenges due to the similarity of physical properties (such as isoelectric point) between samples, and is more often used in the initial purification stage of proteins. In view of the above shortcomings, the prior art discloses a method for extracting immunoglobulins from bovine blood, including adding an anticoagulant to fresh bovine blood and centrifuging out plasma; the plasma is concentrated by ultrafiltration membrane, and the trapped phase is ultrasonically extracted with ethanol, and freeze-dried. This method is excellent in extraction speed, cost-effectiveness and environmental protection, but it has technical disadvantages such as low purity of immunoglobulins, low recovery rate, low activity retention rate, and low economic benefits of industrialization. Summary of the invention

[0005] The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide a method for extracting IgM from bovine blood.

[0006] The present invention is achieved through the following technical scheme: a method for extracting IgM from bovine blood, comprising the following steps:

[0007] S10: adding anticoagulant to fresh bovine blood, mixing well, centrifuging, collecting the supernatant, and obtaining a plasma solution;

[0008] S20: crudely extracting the plasma solution by 3% to 9% polyethylene glycol graded precipitation, and re-dissolving the precipitate with phosphate buffer to obtain a crude extract;

[0009] S30: The crude extract is eluted with a hydroxyapatite column, and the eluate is collected for ultrafiltration and concentration to obtain an IgM concentrate.

[0010] Compared with the prior art, the present invention effectively removes impurity proteins in plasma, such as bovine immune protein complexes, fibrin, bovine albumin and bovine IgG, by combining polyethylene glycol (PEG) graded precipitation with hydroxyapatite (HPA) elution, thereby preparing IgM with a purity of more than 95%. In addition, the extraction and purification process of the present invention increases the recovery rate of IgM to 85% to 90%, which helps to efficiently utilize bovine blood resources and improve the production efficiency and economic benefits of IgM.

[0011] Further, the polyethylene glycol graded precipitation method in step S20 includes: S21: precipitating the plasma solution with a PEG6000 solution with a saturation of 3-5%, discarding the precipitate and retaining the supernatant; S22: precipitating the supernatant with a PEG6000 solution with a saturation of 6-8%, discarding the supernatant and retaining the precipitate; S23: washing the precipitate at least once with a PEG6000 solution with a saturation of 6-9%, and redissolving the precipitate to obtain a crude extract.

[0012] Further, step S20 is performed at 0-8° C.; step S21 includes stirring and mixing the plasma solution and the PEG6000 solution until the final concentration of PEG6000 is 4%, and collecting the supernatant after standing for 30 minutes.

[0013] Further, step S22 includes stirring and mixing the supernatant of step S21 with the PEG6000 solution until the final concentration of PEG6000 is 7%, and collecting the precipitate after standing for 30 minutes and re-dissolving it with a PBS solution.

[0014] Further, step S23 includes stirring and mixing the solution redissolved in step S22 with a PEG6000 solution until the final concentration of PEG6000 is 7.5%, collecting the precipitate and resuspending it with a 7.5% PEG6000 solution, collecting the precipitate by centrifugation and redissolving it with a PB solution.

[0015] Furthermore, the anticoagulant in step S10 is 8% trisodium citrate solution, and the volume ratio of the fresh adult bovine blood to the anticoagulant is 16-20:1; the supernatant in step S1 is mixed with an equal volume of PBS solution to obtain a plasma solution.

[0016] Further, the elution in step S30 includes the following steps: loading the crude extract onto a hydroxyapatite column at a loading flow rate of 5 to 10 mL / min, eluting the hydroxyapatite column with 0.05 M, 0.1 M, 0.2 M, 0.35 M, and 0.5 M PB solutions at pH 6.8 in sequence, and collecting the 0.5 M eluate.

[0017] Furthermore, the ultrafiltration in step S30 uses an ultrafiltration membrane with a molecular weight cutoff of 10 kDa.

[0018] Furthermore, the method further comprises S40: adding trehalose and glycerol to the IgM concentrate of step S30, mixing them evenly and then performing vacuum freeze drying to obtain an IgM finished product.

[0019] Furthermore, the hydroxyapatite column comprises hydroxyapatite, dodecyl ammonium bromide, Triton X-100 and citric acid in a mass ratio of 180 to 220:4 to 20:15 to 25:1.

[0020] For better understanding and implementation, the present invention is described in detail below with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is the IgM standard curve of Experimental Example 1.

[0022] Figure 2 It is the gel electrophoresis diagram of Experimental Example 2, wherein 1 is the Marker, 2 is the recombinant human IgM (1 mg / mL), 3 is the IgM concentrate prepared in Example 1, and 4 is the IgM concentrate prepared in Example 2.

[0023] Figure 3 It is the gel electrophoresis diagram of Experimental Example 2, wherein 1 is the Marker, 2 is the recombinant human IgM (1 mg / mL), 3 is the IgM concentrate prepared in Example 3, and 4 is the IgM finished product prepared in Example 1.

[0024] Figure 4 Schematic diagram of bovine IgM freeze-dried product. DETAILED DESCRIPTION

[0025] As the potential of IgM antibodies in the therapeutic field is explored in depth, the demand for efficient and scalable IgM production processes is becoming increasingly urgent. Given that bovine blood is a natural resource rich in immunoglobulins, this innovative research focuses on optimizing the method of isolating and purifying high-purity IgM from bovine blood, aiming to achieve efficient resource utilization and effective cost control.

[0026] Faced with the expression difficulties and low yield challenges brought by IgM due to its large molecular weight and complex structure, traditional purification methods such as Protein A affinity resin cannot be directly applied due to the non-binding nature of IgM. In addition, the narrow solubility range of IgM significantly increases the technical difficulty and cost of purification. To this end, the present invention systematically explores and integrates a variety of traditional technologies including ammonium sulfate precipitation, isoelectric precipitation, and ion exchange chromatography. Through fine regulation and combination innovation, the effective extraction of IgM is initially achieved, but the problem of low product recovery rate is generally faced. Studies have found that the polyethylene glycol (PEG) precipitation method shows the potential to significantly improve the recovery rate of IgM, and its recovery rate can range from 40% to 84%. However, the large molecular characteristics of PEG6000 become an obstacle to subsequent purification, affecting the purity of the final product. To solve this problem, this study deeply explored the deep purification strategy after PEG precipitation.

[0027] On this basis, we innovatively introduced pretreated hydroxyapatite (HAP) as a purification medium. With its unique surface properties and selective adsorption capacity, HAP has shown significant advantages in removing impurities such as PEG6000 residues, IgG and albumin. By finely regulating the use conditions and purification process of HAP, not only can impurities be effectively removed, but the purity and overall recovery rate of IgM can also be further improved, opening up a new way to obtain high-quality and high-purity IgM products.

[0028] In summary, this study successfully overcame the multiple challenges in the IgM purification process by comprehensively applying multiple purification technologies and innovatively introducing a hydroxyapatite purification step, providing solid technical support and cost-effective optimization solutions for the widespread application of IgM antibody therapy.

[0029] Based on this, the present invention provides a process for extracting, purifying and lyophilizing IgM from bovine blood, comprising the following steps:

[0030] S1: Add 8% trisodium citrate solution to fresh adult bovine blood at a volume ratio of 18:1, mix well, centrifuge the obtained fresh anticoagulated bovine blood at 3000r / min for 15min, collect the supernatant, and add an equal volume of 0.01M PBS solution at pH 6.8 to dilute and obtain plasma.

[0031] S2: Add 30% PEG6000 to the plasma at 0-8°C with stirring to make the final concentration of PEG6000 4%. After standing at 0-8°C for 30 minutes, centrifuge at 0-8°C and 6000r / min, discard the precipitate, and obtain the supernatant. After testing, the main components of the precipitate are bovine immune protein complexes and fibrin. Therefore, the bovine immune protein complexes and fibrin in the plasma are removed by 4% PEG6000 precipitation.

[0032] S3: 30% PEG6000 is added to the supernatant obtained in step S2 at 0-8°C with stirring to make the final concentration of PEG6000 7%, and after standing at 0-8°C for 30 minutes, the mixture is centrifuged at 0-8°C and 6000 r / min, the supernatant is discarded, a precipitate is obtained, and the precipitate is redissolved with PBS (pH 6.8) having a half volume of the supernatant. According to the test, the main components of the supernatant are bovine albumin and bovine IgG, and therefore, the bovine IgM is effectively separated from the bovine albumin and bovine IgG by 7% PEG6000 precipitation.

[0033] S4: Continue to add 30% PEG6000 to the solution re-dissolved in step S3 to make the final concentration of PEG6000 7.5%, centrifuge at 0-8°C and 6000r / min, discard the supernatant, and resuspend the protein with a small amount of 7.5% PEG6000 solution, centrifuge at 0-8°C and 6000r / min, discard the supernatant, and obtain protein precipitation; re-dissolve with 0.01M phosphate buffered saline PB, and adjust the pH to 6.8 to obtain a crude extract, and store the crude extract at 4°C for use. After testing, some bovine albumin and bovine IgG remained in the supernatant, and the bovine IgM, bovine albumin, and bovine IgG were further separated after washing with 7.5% PEG6000.

[0034] S5: The crude extract is passed through a hydroxyapatite HPA column, specifically including: balancing the column with 0.01M phosphate buffer at pH 6.8 and then loading the sample at a loading flow rate of 5 to 10 mL / min, and then gradient eluting with 0.05M, 0.1M, 0.2M, 0.35M, and 0.5M phosphate buffer PB (pH 6.8), and collecting the eluted samples. The protein components in different eluates were determined, and it was found that the main component of the 0.35M eluate was a small amount of residual IgG immunoglobulin, and the main component of the 0.5M eluate was IgM immunoglobulin, and the purity could reach more than 95%.

[0035] The pretreatment of hydroxyapatite HPA filler includes the following steps:

[0036] Hydroxyapatite HPA and water are added to a beaker at a mass ratio of 1:20, and dodecyl ammonium bromide (0.5% of the mass of HPA), Triton X-100 (10% of the mass of HPA), and citric acid (2-10% of the mass of HPA) are added. Boil for 30 minutes under stirring, let stand until the temperature drops to room temperature, neutralize with 1M sodium hydroxide solution to pH 7-8, filter, wash with water 3 times, resuspend and load the column, wash with 0.5M alkali for 2-3V, wash with water to neutrality, balance with 0.01M phosphate buffer at pH 6.8, load the sample, and the loading flow rate is 5-10mL / min. Then, use 0.05M, 0.1M, 0.2M, 0.35M, and 0.5M phosphate buffer PB at pH 6.8 for gradient elution, respectively. The 0.35M elution is mainly a small amount of residual IgG immunoglobulin, and the 0.5M final eluent is IgM immunoglobulin with a purity of more than 95%. The collected bovine IgM solution was concentrated to a concentration of about 5 mg / mL by desalting with 10 kDa ultrafiltration.

[0037] S6: The collected 0.5 M eluate was desalted using 10 kDa ultrafiltration and concentrated to a volume of about one-fourth of the volume of bovine blood or an IgM concentration of about 5 mg / mL to obtain an IgM concentrate.

[0038] S7: Add 2% trehalose and 5% mannitol to the IgM concentrate at a ratio of 1mL: 20-40uL: 20-40uL and mix, and vacuum freeze-dry the mixed IgM concentrate to obtain the IgM finished product. Specifically, the vacuum freeze-drying includes the following steps: pre-cool the mixed IgM concentrate in a refrigerator at 0°C for 2h, then freeze it at -20°C for 5h, and then transfer it to -80°C for 5h to freeze the liquid completely; pre-cool the freeze dryer to -30-40°C, put the bovine IgM sample to be freeze-dried, freeze-dry it overnight under vacuum conditions, obtain the IgM finished product and store it at 4°C.

[0039] The present invention will be further described in detail below in conjunction with specific examples, which are only used to illustrate the present invention and are not intended to limit the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0040] Example 1

[0041] In this example, IgM was extracted from 100 mL of bovine blood by the following steps:

[0042] S1: Add 8% trisodium citrate solution to 100 mL of fresh adult bovine blood at a volume ratio of 18:1, mix well, then centrifuge to collect the supernatant, add an equal volume of 0.01 M PBS solution at pH 6.8 to dilute the supernatant to obtain plasma.

[0043] S2: 30% PEG6000 was added to the plasma at 4°C with stirring to make the final concentration of PEG6000 4%. After standing at 4°C for 30 min, the mixture was centrifuged at 4°C and the supernatant was collected.

[0044] S3: At 4°C, add 30% PEG6000 to the supernatant obtained in step S2 with stirring to make the final concentration of PEG6000 7%. After standing at 4°C for 30 min, centrifuge at 4°C, discard the supernatant, obtain the precipitate, and re-dissolve the precipitate with PBS (pH 6.8) with half the volume of the supernatant.

[0045] S4: Continue to add 30% PEG6000 to the solution re-dissolved in step S3 to make the final concentration of PEG6000 7.5%, centrifuge at 4°C and 6000 r / min, discard the supernatant, and resuspend the protein with a small amount of 7.5% PEG6000 solution, centrifuge at 4°C and 6000 r / min, discard the supernatant, and obtain a protein precipitate; re-dissolve the protein precipitate with 30 mL 0.01 M phosphate buffered saline PB, and adjust the pH to 6.8 to obtain a crude extract, and store the crude extract at 4°C for use.

[0046] S5: The crude extract redissolved in step S5 is passed through a hydroxyapatite HPA column, specifically comprising: balancing the column with 0.01M phosphate buffer at pH 6.8 and then loading the sample at a loading flow rate of 5 to 10 mL / min, and then gradient eluting with 0.05M, 0.1M, 0.2M, 0.35M, and 0.5M phosphate buffer PB (pH 6.8), respectively, and collecting the 0.5M eluate.

[0047] S6: The collected 0.5 M eluate was desalted using 10 kDa ultrafiltration and concentrated to 25 mL to obtain an IgM concentrate.

[0048] S7: Add 2% trehalose and 5% mannitol to the IgM concentrate at a ratio of 1mL: 20-40uL: 20-40uL and mix, and vacuum freeze-dry the mixed IgM concentrate to obtain the IgM finished product. Specifically, the vacuum freeze-drying includes the following steps: pre-cool the mixed IgM concentrate in a refrigerator at 0°C for 2h, then freeze it at ~20°C for 5h, and then transfer it to ~80°C for 5h to freeze the liquid completely; pre-cool the freeze plate of the freeze dryer to ~30~~40°C, put the bovine IgM sample to be freeze-dried, freeze-dry it overnight under vacuum conditions, obtain the IgM finished product and store it at 4°C.

[0049] The purity of the IgM product was determined by HPLC, and the results showed that the purity of the IgM prepared in this example was above 95%.

[0050] Experimental Example 2

[0051] The method of this embodiment is similar to that of Embodiment 1, except that the volume of bovine blood in this embodiment is 200 mL, and in step S4, 60 mL of 0.01 M phosphate buffered saline (PB) is used to redissolve the protein precipitate; in step S6, the eluate is concentrated to 50 mL.

[0052] The purity of the IgM product was determined by HPLC, and the results showed that the purity of the IgM prepared in this example was above 95%.

[0053] Experimental Example 3

[0054] The method of this embodiment is similar to that of Embodiment 1, except that the volume of bovine blood in this embodiment is 500 mL, and in step S4, 200 mL of 0.01 M phosphate buffered saline (PB) is used to re-dissolve the protein precipitate; in step S6, the eluate is concentrated to 135 mL.

[0055] The purity of the IgM product was determined by HPLC, and the results showed that the purity of the IgM prepared in this example was above 95%.

[0056] Test Example 1

[0057] The ELISA method was used to determine the IgM concentration of the bovine blood and the IgM concentration of the IgM concentrate in Examples 1 to 3, which specifically includes the following steps:

[0058] 1. Warm the concentrated washing solution (20×) to room temperature or 37°C, then dilute the concentrated washing solution 20 times with distilled water to prepare a 1× washing solution.

[0059] 2. Insert a sufficient number of microwells into the microplate according to the number of samples to be tested, and add 100 μL of bovine IgM standards (0, 100, 300, 600, 1200, 2400 ppb) or samples of different concentrations into the microwells.

[0060] 3. Incubate at room temperature for 30 minutes, discard the liquid in the microwells, wash the microwells with 1× washing solution, repeat the washing 4 times, and remove the residual washing solution.

[0061] 4. Add 100 μL of enzyme-labeled conjugate to the microwells and incubate at room temperature in the dark for 30 minutes. After incubation, wash the microplate 5 times.

[0062] 5. Add 100 μL of substrate reagent to each microwell, react at room temperature in the dark for 15 minutes, and add 100 μL of stop solution to each well after color development. Mix gently on a horizontal surface, measure the absorbance at 450 nm, draw a standard curve and calculate the concentration of bovine IgM in the sample.

[0063] Referring to Table 1, the IgM recovery rate of the extraction and purification process of IgM in bovine blood provided by the present invention is as high as 85% to 90%, which is significantly higher than the recovery rate of the existing IgM extraction and purification method, and the purity of the IgM prepared by the present invention is greater than 95%. Therefore, the method provided by the present invention is simple to operate, significantly improves the purity and recovery rate of IgM, and helps to improve the utilization rate of bovine blood resources.

[0064] Table 1 IgM recovery rate

[0065]

[0066] Test Example 2

[0067] The IgM concentrates in Examples 1 to 3 and the lyophilized IgM finished product in Example 1 were subjected to SDS-PAGE gel electrophoresis, comprising the following steps:

[0068] 1. Clean the glass plate: Use detergent to scrub the glass plate, then rinse with tap water and distilled water and dry it.

[0069] 2. Glue pouring: Align the glass plates and put them into the clamps to clamp them tightly, then clamp them vertically on the rack to prepare for glue pouring; prepare 12% separation gel, add TEMED and shake well immediately before pouring; after the separation gel solidifies, prepare 5% concentrated gel, add TEMED and shake well immediately before pouring; after the concentrated gel is filled, insert the comb into the concentrated gel, and after the concentrated gel solidifies, pinch the two sides of the comb with both hands and gently pull it out vertically upwards. Put the gel into the electrophoresis tank.

[0070] 3. Sample loading: Measure the protein content and calculate the volume of the solution containing 50ng of protein as the sample loading amount. Add 5×SDS loading buffer to the sample to a final concentration of 1×. Boil the sample in boiling water for 5 minutes before loading to denature the protein. Add enough electrophoresis solution and start preparing for sample loading.

[0071] 4. Electrophoresis: The electrophoresis time is generally 1.5 hours, the voltage is 80V for 30 minutes, and then 120V for 50 minutes. Electrophoresis can be terminated when bromophenol blue just runs out, and transfer to the membrane is performed.

[0072] 5. After transfer, stain the membrane with bromophenol blue staining solution on a shaker for 40 minutes, pour out the staining solution, add decolorizing solution and decolorize on a shaker until the background color is completely removed and the protein bands appear.

[0073] Electrophoresis results refer to Figure 2 and Figure 3 .

[0074] In summary, compared with the prior art, the present invention has the following advantages and effects:

[0075] (1) The present invention effectively removes impurity proteins in plasma, such as bovine immune protein complexes, fibrin, bovine albumin and bovine IgG, by combining polyethylene glycol (PEG) graded precipitation with hydroxyapatite (HPA) elution, thereby preparing IgM with a purity of more than 95%. This high-purity IgM has higher safety and effectiveness in drug development and clinical application.

[0076] (2) Compared with the traditional method, the extraction and purification process of the present invention significantly improves the recovery rate of IgM to 85% to 90%. This means that more IgM can be extracted from the same amount of bovine blood raw material, thereby improving production efficiency and economic benefits.

[0077] (3) The present invention effectively retains the biological activity of IgM by optimizing the operating conditions and adding appropriate protective agents (such as trehalose and glycerol) during the extraction and purification process. This makes the prepared IgM have a stronger immune enhancement effect in preventing and treating bacterial infections.

[0078] (4) The vacuum freeze-dried IgM finished product of the present invention can maintain high stability during storage and transportation, which helps to extend the shelf life of the product and reduce the activity loss caused by improper storage conditions.

[0079] (5) The method of the present invention uses environmentally friendly reagents and processes during the extraction and purification process, reducing the emission of harmful substances. At the same time, by efficiently utilizing cattle blood resources, the generation of waste is reduced, reducing pollution to the environment.

[0080] (6) The method of the present invention is simple to operate, low in cost, and easy to realize industrial production. With the increasing demand for IgM, the extraction and purification process provided by the present invention has broad market prospects and application value.

[0081] (7) By efficiently extracting and purifying IgM, the present invention provides a new approach for the comprehensive utilization of cattle blood resources, which helps to reduce the waste of cattle blood resources and improve the economic and ecological benefits of animal husbandry.

[0082] The above-mentioned embodiments only express several implementation methods of the present invention, and the description is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, and the present invention is also intended to include these modifications and modifications.

Claims

1. A method for extracting IgM from bovine blood, characterized in that: The steps include: S10: adding anticoagulant to fresh bovine blood, mixing well, centrifuging, collecting the supernatant, and obtaining a plasma solution; S20: crudely extracting the plasma solution by 3% to 9% polyethylene glycol graded precipitation, and re-dissolving the precipitate with phosphate buffer to obtain a crude extract; S30: The crude extract is eluted with a hydroxyapatite column, and the eluate is collected for ultrafiltration and concentration to obtain an IgM concentrate.

2. The method according to claim 1, characterized in that: The polyethylene glycol graded precipitation method in step S20 includes: S21: precipitating the plasma solution with a PEG6000 solution with a saturation of 3-5%, discarding the precipitate and retaining the supernatant; S22: precipitating the supernatant with a PEG6000 solution with a saturation of 6-8%, discarding the supernatant and retaining the precipitate; S23: washing the precipitate at least once with a PEG6000 solution with a saturation of 6-9%, and redissolving the precipitate to obtain a crude extract.

3. The method according to claim 2, characterized in that: Step S20 is performed at 0-8°C; Step S21 includes stirring and mixing the plasma solution and the PEG6000 solution until the final concentration of PEG6000 is 4%, and collecting the supernatant after standing for 30 minutes.

4. The method according to claim 2, characterized in that: Step S22 includes stirring and mixing the supernatant of step S21 with the PEG6000 solution until the final concentration of PEG6000 is 7%, standing for 30 minutes, collecting the precipitate and re-dissolving it with a PBS solution.

5. The method according to claim 2, characterized in that: Step S23 includes stirring and mixing the solution redissolved in step S22 with the PEG6000 solution until the final concentration of PEG6000 is 7.5%, collecting the precipitate and resuspending it with a 7.5% PEG6000 solution, collecting the precipitate by centrifugation and redissolving it with a PB solution.

6. The method according to claim 2, characterized in that: In step S10, the anticoagulant is 8% trisodium citrate solution, and the volume ratio of the fresh adult bovine blood to the anticoagulant is 16-20:1; the supernatant of step S1 is mixed with an equal volume of PBS solution to obtain a plasma solution.

7. The method according to claim 6, characterized in that: The elution in step S30 includes the following steps: loading the crude extract onto a hydroxyapatite column at a loading flow rate of 5 to 10 mL / min, eluting the hydroxyapatite column with 0.05 M, 0.1 M, 0.2 M, 0.35 M, and 0.5 M PB solutions at pH 6.8 in sequence, and collecting the 0.5 M eluate.

8. The method according to claim 7, characterized in that: The ultrafiltration in step S30 uses an ultrafiltration membrane with a molecular weight cutoff of 10 kDa.

9. The method according to claim 8, characterized in that: The method further comprises S40: adding trehalose and glycerol to the IgM concentrated solution of step S30, mixing evenly and then performing vacuum freeze drying to obtain an IgM finished product.

10. The method according to claim 9, characterized in that: The hydroxyapatite column comprises hydroxyapatite, dodecyl ammonium bromide, Triton X-100 and citric acid in a mass ratio of 180-220:4-20:15-25:1.

Citation Information

Patent Citations

  • IgM purification method

    CN112409477A

  • Method for obtaining composition comprising immunoglobulin M of human plasma origin

    CN115768789A

  • Protein purification methods

    US20150376231A1